Clinical Trial News
CBD Shows Promise in Curbing SARS-CoV-2 Replication, Clinical Trials Needed
- Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials.
- Studies indicate CBD acts post-infection, blocking virus replication, while THC and other cannabinoids do not show the same antiviral effects.
- Researchers emphasize that current evidence does not support self-medication with CBD and highlight the importance of vaccines and antibody drugs.
- Clinical trials are underway to assess CBD's efficacy in treating COVID-19, with challenges in enrolling patients due to milder Omicron cases.
Johnson & Johnson MedTech Receives CE Mark Approval for Advanced Dual Energy THERMOCOOL SMARTTOUCH SF Catheter
Johnson & Johnson MedTech has achieved European CE mark approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, a breakthrough in treating cardiac arrhythmias by integrating radiofrequency and pulsed field energy. This innovation allows for seamless energy mode switching during procedures, improving treatment flexibility and effectiveness for paroxysmal atrial fibrillation.
Adimab Announces 2021 Clinical Pipeline Update with 12 New Partner Programs
Adimab, LLC, a leader in antibody discovery and optimization, reported that 12 new partner programs entered clinical development in 2021, increasing the total number of clinical programs to 55. The most advanced program, Tyvyt® (Sintilimab), is currently marketed in China and has a BLA filed with the FDA for U.S. approval. Adimab's partners exercised 10 commercial licenses in 2021, bringing the total optioned programs to over 85.
Prophylactic Tranexamic Acid in Hematologic Malignancy Patients: A Randomized Clinical Trial
A randomized clinical trial investigated the effectiveness of prophylactic tranexamic acid (TXA) in reducing bleeding incidence among patients with hematologic malignancies. The study found no significant difference in bleeding risk between TXA and placebo groups.
EDAP Announces Positive Pre-clinical Results for HIFU Ablation in Pancreatic Cancer Treatment
EDAP TMS S.A. has published positive pre-clinical results in the journal Cancers, showcasing the potential of intraoperative high intensity focused ultrasound (HIFU) ablation for treating locally advanced pancreatic adenocarcinoma (LAPA). This study represents a significant step towards developing a clinical treatment for LAPA, a condition with a less than 5% five-year survival rate.
Personalized Prediction Model for Alzheimer's Disease Progression and Donepezil Treatment Effects
A new study has developed a personalized prediction model for Alzheimer's disease progression and the effects of donepezil treatment, highlighting the importance of individual patient characteristics in predicting outcomes.
IDEAYA Biosciences Announces Corporate and Portfolio Updates at J.P. Morgan Healthcare Conference
IDEAYA Biosciences, Inc. shared key corporate and portfolio updates at the J.P. Morgan 40th Annual Healthcare Conference, highlighting its strong financial position, progress in clinical trials, and future plans for its oncology-focused precision medicine developments.
Maze Therapeutics Secures $190 Million to Advance Precision Medicine Programs
- Maze Therapeutics has raised $190 million to support its nine precision medicine programs targeting genetically defined diseases.
- The funding will advance clinical trials for MZE001, a treatment for Pompe disease, expected to begin in the first half of 2022.
- Maze's Compass platform, designed to accelerate drug discovery through genetic and genomic data analysis, will also be expanded.
- The financing will also support programs for chronic kidney disease and amyotrophic lateral sclerosis (ALS).
Ascendis Pharma A/S Updates on Vision 3x3 Strategy and 2022 Milestones
Ascendis Pharma A/S provided an update on its Vision 3x3 strategic roadmap and key milestones for 2022 at the 40th Annual J.P. Morgan Healthcare Conference. The company highlighted its progress in 2021, including the U.S. launch of SKYTROFA®, and outlined its plans for clinical data readouts and regulatory submissions across its endocrinology rare disease and oncology portfolios in 2022.
IceCure Medical CEO Highlights 2021 Achievements and 2022 Objectives
IceCure Medical Ltd. CEO Eyal Shamir outlines the company's 2021 achievements, including progress in the ICE3 clinical trial and expansion of the ProSense® system's global distribution network, and sets key business objectives for 2022, focusing on regulatory clearances and the development of next-generation cryoablation systems.